Inhibition of WEE1 in combination with DNA-damaging agents has been explored as a strategy for tumors with dysregulated p53 and numerous pre-clinical and clinical studies demonstrate preferential sensitivity of TP53 mutated tumors [17–19]; though this has been equally contested by other investigators in various different cancer types [20, 21]. Here, WEE1 is linked to cancer.